BIOCYTOGEN
3.1.2023 15:24:36 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Optics and Photonics Community Invited to SPIE Photonics West 202714.10.2026 16:01:00 CEST | Press release
Thousands from around the globe will share research breakthroughs and industry innovations in optics and photonics SPIE, the international society for optics and photonics, invites the global optics and photonics community to register for SPIE Photonics West 2027, happening 30 January–4 February at the Moscone Center in San Francisco, California. The dynamic week draws 24,000 researchers, engineers, students, and business leaders from around the globe, providing technical presentations, exhibitions, and networking opportunities that fuel collaboration and real-world innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013654749/en/ SPIE Photonics West will be held 30 January-4 February 2027 in San Francisco, California. The annual event brings together 24,000 people from the global optics and photonics community to foster collaboration and innovation. SPIE anticipates more than 4,500 presentations will be given acro
Toluna Appoints Amy Fenton as Chief Executive Officer14.10.2026 15:30:00 CEST | Press release
Appointment completes the planned succession announced on October 8, 2026. Founder Frédéric Charles Petit continues as Board member, Senior Advisor and Shareholder. Toluna, a global leader in consumer insights and market research technology, today announces the appointment of Amy Fenton as Chief Executive Officer, effective October 15, 2026. Ms. Fenton succeeds Frédéric Charles Petit, who founded Toluna and has led the company for 25 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014103169/en/ Amy Fenton appointed as new Chief Executive Officer, Toluna The appointment concludes the structured succession process announced on October 8, 2026, led by the Board in close consultation with Mr. Petit and supported by a leading executive search firm. Ms. Fenton brings more than 30 years of leadership experience in the insights and analytics industry. She joins Toluna from MarketCast, where she served as Chief Executive Off
BanyanGlobal Family Business Advisors Named Family Business Advisory Practice of the Year at the STEP Private Client Awards for the Fourth Time14.10.2026 15:05:00 CEST | Press release
The international recognition, also awarded to the firm in 2018, 2020 and 2021, honors Banyan's approach of pairing governance with the skills and confidence families need for long-term ownership BanyanGlobal Family Business Advisors ("Banyan") has been named Family Business Advisory Practice of the Year at the 21st annual STEP Private Client Awards, one of the most respected international honors in the private client profession. It is the fourth time Banyan has won the category, following wins in 2018, 2020 and 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013883351/en/ Kelly Greig, STEP Board Member and Dennis Jaffe, BanyanGlobal Family Business Advisors at the awards ceremony. BanyanGlobal won the Family Business Advisory Practice of the Year at the 21st Annual STEP Private Client Awards. The independent judging panel singled out Banyan's approach: "BanyanGlobal Family Business Advisors has redefined family busi
Telekom Srbija Group Expands AI Investment and Strengthens U.S. Technology Partnerships14.10.2026 15:02:00 CEST | Press release
Leading Southeast European Telecommunications and Technology Group Advances AI Innovation Through International Collaboration, Startup Investments and 5G Infrastructure. Following the October 1 agreement between Serbia and the United States to strengthen cooperation in artificial intelligence (AI), Telekom Srbija Group is expanding its AI investment and deepening relationships with leading U.S. technology companies as part of its strategy to develop the next generation digital services. As part of these efforts, Telekom Srbija Group has engaged with the U.S. State Department, Department of Commerce and Export-Import Bank to explore opportunities for technology cooperation and project financing, with the ambition of becoming a preferred regional partner for U.S. companies. “Artificial intelligence represents one of the greatest opportunities for the future of telecommunications and digital services,” said Vladimir Lučić, CEO of Telekom Srbija Group. “We have been investing in this techn
Lenovo Uncovers What Happens When Entrepreneurs Look Beyond Borders for Support14.10.2026 15:00:00 CEST | Press release
New documentary series follows small business founders from around the world as unexpected connections and technology spark fresh ideas, new approaches to business challenges and opportunities for growth Today, Lenovo debuts the first episode of its new documentary series from Backing Every Business, its global initiative designed to connect small businesses with the people, technology and support they need to grow and thrive. The series features five businesses participating in Twinning, Lenovo’sprogram that brings small business founders from around the world together, connecting them through mentorship across shared growth goals, access to resources including technology, AI training, funding designed to help address real business challenges and turn new ideas into action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014736241/en/ The four-part series follows entrepreneurs from Japan, Mexico, the U.K. and the U.S. as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom